These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17891169)

  • 1. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells.
    Barbetti V; Gozzini A; Rovida E; Morandi A; Spinelli E; Fossati G; Mascagni P; Lübbert M; Dello Sbarba P; Santini V
    Oncogene; 2008 Mar; 27(12):1767-78. PubMed ID: 17891169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [ITF-2357 on inhibition myeloid leukemic cell lines cells proliferation in vitro and its mechanism].
    Yu WJ; Wang L; You LS; Mei C; Ma QL; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):366-70. PubMed ID: 22781793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.
    Klisovic MI; Maghraby EA; Parthun MR; Guimond M; Sklenar AR; Whitman SP; Chan KK; Murphy T; Anon J; Archer KJ; Rush LJ; Plass C; Grever MR; Byrd JC; Marcucci G
    Leukemia; 2003 Feb; 17(2):350-8. PubMed ID: 12592335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter.
    Tabe Y; Konopleva M; Kondo Y; Contractor R; Jin L; Ruvolo V; Tsutsumi-Ishii Y; Miyake K; Miyake N; Ohsaka A; Nagaoka I; Issa JP; Andreeff M
    Ann Hematol; 2006 Oct; 85(10):689-704. PubMed ID: 16832676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines.
    Berg T; Guo Y; Abdelkarim M; Fliegauf M; Lübbert M
    Leuk Res; 2007 Apr; 31(4):497-506. PubMed ID: 17056112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of DNA methylation and histone deacetylation independently relieve AML1/ETO-mediated lysozyme repression.
    Claus R; Fliegauf M; Stock M; Duque JA; Kolanczyk M; Lübbert M
    J Leukoc Biol; 2006 Dec; 80(6):1462-72. PubMed ID: 17000900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells.
    Wang J; Saunthararajah Y; Redner RL; Liu JM
    Cancer Res; 1999 Jun; 59(12):2766-9. PubMed ID: 10383127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells.
    Golay J; Cuppini L; Leoni F; Micò C; Barbui V; Domenghini M; Lombardi L; Neri A; Barbui AM; Salvi A; Pozzi P; Porro G; Pagani P; Fossati G; Mascagni P; Introna M; Rambaldi A
    Leukemia; 2007 Sep; 21(9):1892-900. PubMed ID: 17637810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.
    Tabe Y; Jin L; Contractor R; Gold D; Ruvolo P; Radke S; Xu Y; Tsutusmi-Ishii Y; Miyake K; Miyake N; Kondo S; Ohsaka A; Nagaoka I; Andreeff M; Konopleva M
    Cell Death Differ; 2007 Aug; 14(8):1443-56. PubMed ID: 17464329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.
    Barbetti V; Gozzini A; Cheloni G; Marzi I; Fabiani E; Santini V; Dello Sbarba P; Rovida E
    Epigenetics; 2013 Feb; 8(2):210-9. PubMed ID: 23321683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AML1-ETO triggers epigenetic activation of early growth response gene l, inducing apoptosis in t(8;21) acute myeloid leukemia.
    Fu L; Huang W; Jing Y; Jiang M; Zhao Y; Shi J; Huang S; Xue X; Zhang Q; Tang J; Dou L; Wang L; Nervi C; Li Y; Yu L
    FEBS J; 2014 Feb; 281(4):1123-31. PubMed ID: 24314118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.
    Ter Elst A; Ma B; Scherpen FJ; de Jonge HJ; Douwes J; Wierenga AT; Schuringa JJ; Kamps WA; de Bont ES
    Cancer Res; 2011 Apr; 71(7):2761-71. PubMed ID: 21447743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins.
    Moldenhauer A; Frank RC; Pinilla-Ibarz J; Holland G; Boccuni P; Scheinberg DA; Salama A; Seeger K; Moore MA; Nimer SD
    J Leukoc Biol; 2004 Sep; 76(3):623-33. PubMed ID: 15197237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.
    Fliegauf M; Stock M; Berg T; Lübbert M
    Oncogene; 2004 Dec; 23(56):9070-81. PubMed ID: 15489901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO.
    Duque-Afonso J; Yalcin A; Berg T; Abdelkarim M; Heidenreich O; Lübbert M
    Oncogene; 2011 Jul; 30(27):3062-72. PubMed ID: 21577204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
    Gozzini A; Santini V
    Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
    Elsässer A; Franzen M; Kohlmann A; Weisser M; Schnittger S; Schoch C; Reddy VA; Burel S; Zhang DE; Ueffing M; Tenen DG; Hiddemann W; Behre G
    Oncogene; 2003 Aug; 22(36):5646-57. PubMed ID: 12944913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic silencing of Bcl-2, CEBPA and p14(ARF) by the AML1-ETO oncoprotein contributing to growth arrest and differentiation block in the U937 cell line.
    Zhuang WY; Cen JN; Zhao Y; Chen ZX
    Oncol Rep; 2013 Jul; 30(1):185-92. PubMed ID: 23673926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.
    Ferrara FF; Fazi F; Bianchini A; Padula F; Gelmetti V; Minucci S; Mancini M; Pelicci PG; Lo Coco F; Nervi C
    Cancer Res; 2001 Jan; 61(1):2-7. PubMed ID: 11196162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.